Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors

RATIONALE: Drugs used in chemotherapy, such as methoxyamine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with temozolomide may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of methoxyamine when given together with temozolomide in treating patients with advanced solid tumors.

Study Overview

• Status: Completed
• Conditions: Unspecified Adult Solid Tumor, Protocol Specific
• Intervention / Treatment: Drug: Methoxyamine; Drug: Temozolomide

Detailed Description

OBJECTIVES:

• To determine the maximum tolerated dose of methoxyamine given in conjunction with temozolomide in patients with and without CNS disease.
• To determine the dose limiting toxicities of the combination of methoxyamine and temozolomide in patients with and without CNS disease.
• To determine the pharmacokinetics of these two agents when given alone or in combination, as well as the pharmacokinetic profile of methoxyamine after single one-hour IV administration.
• To determine relative DNA damage, as single or double strand breaks by comet assay in blood mononuclear cells which will serve as a surrogate for tumor response to the drug combination.

OUTLINE: This is a dose escalation study of methoxyamine.

Patients receive oral temozolomide for 5 days every 28 days and methoxyamine IV over 1 hour every 28 days. Methoxyamine IV administration will follow, within 5 minutes, initial administration of TMZ on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for correlative studies. Samples are analyzed for methoxyamine and temozolomide pharmacokinetics, apurinic/apyrimidinic sites, and DNA strand break determination by comet assay.

• Study Type: Interventional
• Enrollment (Actual): 66
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have a histologically confirmed solid tumor that is considered incurable and is not amenable to conventional surgical, radiation therapy or chemotherapy treatment programs.
• Prior chemotherapy and/or radiation are allowed. At least 3 weeks must have elapsed since prior large-field radiation therapy; patients must have been off previous anti-cancer therapy for at least 3 weeks (6 weeks for mitomycin-C and nitrosoureas); and recovered from all treatment related toxicity to < grade 1 according to NCI CTCAE version 3.0 (with the exception of alopecia and radiation-induced taste changes). Prior temozolomide treatment is not restricted.
• ECOG performance status (PS) 0-2 (Karnofsky PS 50-100%)
• Life expectancy ≥ 12 weeks

• Patients must have normal organ and marrow function as defined below:

  • Absolute neutrophil count ≥ 1,500/μL
  • Platelet count ≥ 100,000/μL
  • Hemoglobin ≥ 10.0 g/dL
  • Total bilirubin ≤ 1.5 mg/dL
  • AST ≤ 2.5 times upper limit of normal
  • Creatinine ≤ 1.5 mg/dL and/or creatinine clearance ≥ 60 mL/min
• Patients with known primary or metastatic CNS disease, are eligible for participation in cohort B, but not in cohort A.
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients may not be receiving any other investigational agents or have received other investigational agents for at least 3 weeks.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant and lactating women are excluded from this study because the methoxyamine and temozolomide combination is likely to be teratogenic.
• NYHA classification III or IV heart disease
• Patients with known primary or metastatic CNS disease (cohort B) are not eligible if they have a mini mental status exam score < 15 or evidence of leptomeningeal disease.
• Patients with pre-existing neurologic toxicity > grade1 (as per CTCAE, version 3.0) are not eligible for participation in cohort A.
• Patients screened for participation in cohort B with pre-existing neurologic toxicity > grade 2 (as per CTCAE, version 3.0) are not eligible, unless pre-existing neurologic toxicity is documented in detail and patient's participation in the trial has been approved by the neuro-oncology team at participating institutions.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Non-CNS Disease; A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which <2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.	Drug: Methoxyamine; For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.; Other Names: NSC-3801; MX; Drug: Temozolomide; Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.; Other Names: TMZ
EXPERIMENTAL: CNS Disease; A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where <2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.	Drug: Methoxyamine; For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.; Other Names: NSC-3801; MX; Drug: Temozolomide; Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.; Other Names: TMZ

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose of methoxyamine	A total of 38 patients were analyzed to determine the maximum tolerated dose of methoxyamine in this study and this was determined in the non-CNS arm. An initial 6 patients received treatment with continuous dosing of methoxyamine and based on an assessment of pharmacokinetics, in this group, the study was revised to administer methoxyamine as a bolus dose. Thirty-eight patients received this type of dosing.	Courses repeat every 28 days in the absence of unacceptable toxicity.
Dose limiting toxicities of the combination of methoxyamine and temozolomide	The 38 patients receiving bolus dosing of methoxyamine in this trial were used to determine any dose limiting toxicities.	Courses repeat every 28 days in the absence of unacceptable toxicity.
Pharmacokinetics methoxyamine and temozolomide, when given alone or in combination	Thirty-eight patients were analyzed per the schedule above (after an initial 6 patients treated per an alternative dosing schedule).	Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects.

Collaborators and Investigators

• Sponsor: Case Comprehensive Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Jennifer Eads, MD, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 16, 2007
• Primary Completion (ACTUAL): March 8, 2017
• Study Completion (ACTUAL): March 8, 2017

Study Registration Dates

• First Submitted: May 1, 2009
• First Submitted That Met QC Criteria: May 1, 2009
• First Posted (ESTIMATE): May 4, 2009

Study Record Updates

• Last Update Posted (ACTUAL): February 22, 2019
• Last Update Submitted That Met QC Criteria: February 20, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Keywords: unspecified adult solid tumor, protocol specific
• Additional Relevant MeSH Terms: Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Temozolomide
• Other Study ID Numbers: CASE1Y05 (OTHER: Case Comprehensive Cancer Center); P30CA043703 (U.S. NIH Grant/Contract); WIRB-20070151 (OTHER: Western Institutional Review Board); NCI-2009-01286 (REGISTRY: NCI)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No